Drugs / YD01-2022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05990517 | Feb 2023 → Aug 2024 | post-surgical hypoinsulinemia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YD01-2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990517 ↗ |
| Modality | Cell therapy | “Human islet cells were isolated and expanded in vitro” NCT05990517 ↗ |
| Route | Other | “These islet cells will be infused into the hepatic portal vein.” NCT05990517 ↗ |